Tech Company Inital Public Offerings
Frequency Therapeutics IPO
Frequency Therapeutics, based in Woburn, debuted as a public company on 10/2/2019.
Transaction Overview
Company Name
Announced On
10/2/2019
Transaction Type
IPO
Amount
$84,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $90.0 million to advance the clinical development of FX-322 for the treatment of SNHL, including the completion of our planned Phase 2a clinical trial for FX-322; approximately $32.0 million to advance the development of other product candidates using our PCA platform, including the submission of an IND for an MS product candidate; and the remainder for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
19 Presidential Way
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Website
Email Address
Overview
Frequency Therapeutics (Nasdaq: FREQ) develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/1/2019: Vertos Medical venture capital transaction
Next: 10/2/2019: OnCorps venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC transactions on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs